VEXAS Clinical Trials

8 recruitingLast updated: May 21, 2026

There are 8 actively recruiting vexas clinical trials across 27 countries. Studies span Phase 2, Phase 1. Top locations include Milan, Italy, Roma, Italy, Padova, Italy. Updated daily from ClinicalTrials.gov.


VEXAS Trials at a Glance

8 actively recruiting trials for vexas are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Milan, Roma, and Padova. Lead sponsors running vexas studies include Gruppo Italiano Malattie EMatologiche dell'Adulto, Monash University, and Groupe Francophone des Myelodysplasies.

Browse vexas trials by phase

About VEXAS Clinical Trials

Looking for clinical trials for VEXAS? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new VEXAS trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about VEXAS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

VEXAS Syndrome
Technische Universität Dresden500 enrolled17 locationsNCT06377462
Recruiting
Phase 2

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

VEXAS SyndromeVEXAS
Swedish Orphan Biovitrum78 enrolled39 locationsNCT06782373
Recruiting
Phase 2

Momelotinib in VEXAS Syndrome

VEXAS SyndomeMyelo Dysplastic Syndrome
Groupe Francophone des Myelodysplasies57 enrolled11 locationsNCT07098936
Recruiting

HRQoL and Financial Toxicity in Patients With VEXAS Syndrome

VEXAS
Gruppo Italiano Malattie EMatologiche dell'Adulto100 enrolled17 locationsNCT06657846
Recruiting
Phase 1

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

VEXAS SyndromeVEXASE1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome
Washington University School of Medicine15 enrolled1 locationNCT06538181
Recruiting

Autoimmune and Autoinflammatory Genetics Study

Rheumatic diseaseAutoimmune DiseaseAutoinflammatory Disease+1 more
NYU Langone Health1,500 enrolled2 locationsNCT06004349
Recruiting

AutoInflammatory Disease Alliance Registry (AIDA)

VEXAS SyndromeCastleman DiseaseUveitis+8 more
University of Siena3,500 enrolled112 locationsNCT05200715
Recruiting

Aplastic Anaemia and Other Bone Marrow Failure Syndromes Registry (AAR)

Hereditary Predisposition to Haematological Malignancy (HPHM)Aplastic AnaemiaVEXAS Syndrome+1 more
Monash University1,000 enrolled37 locationsACTRN12623000461695